Sub-Visible Particles: Impact On Therapeutic Proteins
News Jun 07, 2013
SP Scientific has announced a new LyoLearn webinar, due to run on 27th June 2013, entitled 'Sub-visible Particles: Impacts on Aggregation Pathways, Adverse Immunogenicity and Regulatory Expectations for Therapeutic Proteins'.
During the session, Dr. John Carpenter Professor of Pharmaceutical Sciences and Co-Director of the Center for Pharmaceutical Biotechnology, University of Colorado (USA), discusses key areas and presents the latest results from his research.
In addition, he will highlight the particle counting instruments that have been vital to the progress made to date.
Over the past several years there has been greatly increasing attention on sub-visible particles in therapeutic protein products.
Initially, much of the discussion and debate in the field has centred on the utility and need for quantifying particles smaller than 10 micron.
As appropriate instruments and quantitative methods have been developed, valuable progress has occurred in a wide range of drug development areas and more clearly defining critical quality attributes and regulatory expectations related to sub-visible particles.
SP Scientific's program of free educational webinars delivered by industry experts are devoted to lyophilization, freeze-drying and related topics.
LyoLearn webinars follow a 45-minute format for the presentations with a Q&A session immediately afterwards.
Chemists Design 'Mini-ecosystems' to Test Drug FunctionNews
Scripps Research scientists have solved a major problem in chemistry and drug development by using droplet-sized 'miniecosystems' to quickly see if a molecule can function as a potential therapeutic.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Antibody Shrinks Tumors of Patients with Advanced Skin CancerNews
Clinical trials show that an immune checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of a common skin cancer.READ MORE